

Selección de ensayos clínicos cubanos de productos para el tratamiento del cáncer publicados en revistas médicas de impacto.

Alfonso S, Diaz RM, de la Torre A, Santiesteban E, Aguirre F, Pérez K, et al. [1E10 anti-idiotypic vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther.](#) 2007 Dic;6(12):1847-52.

Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I. [Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons.](#) Open, prospective study. BMC Cancer. 2009 Jul 30;9:262.

García B, Neningen E, de la Torre A, Leonard I, Martínez R, Viada C, et al. [Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.](#) Clin Cancer Res. 2008 Feb 1;14(3):840-6.

Gavilondo JV, Hernández-Bernal F, Ayala-Ávila M, de la Torre AV, de la Torre J, Morera-Díaz Y, et al. [Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.](#) Vaccine. 2014 Abr 17;32(19):2241-50.

Pimentel G, García I, González J, Pérez L, Velazco M, Calderón C, et al. [Phase I clinical trial of the \(131\)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment.](#) Cancer Biother Radiopharm. 2011 Jun;26(3):353-63.

Neningen Vinageras E, de la Torre A, Osorio Rodríguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, et al. [Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.](#) J Clin Oncol. 2008 Mar 20;26(9):1452-8.

Osorio M, Gracia E, Rodríguez E, Saurez G, Arango Mdel C, Noris E, et al. [Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study.](#) Cancer Biol Ther. 2008 Abr;7(4):488-95.

Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, et al. [CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoacceptor domain.](#) Translational and clinical research. Mol Cell Biochem. 2011 Oct;356(1-2):45-50.

Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, et al. [Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.](#) Cancer Biol Ther. 2012 Jun;13(8):600-5.

Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, et al. [Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck](#). Cancer Biol Ther. 2010 Mar 1;9(5):343-9.

Rodríguez-Vera L, Ramos-Suzarte M, Fernández-Sánchez E, Soriano JL, Guitart CP, Hernández GC, Jacobo-Cabral CO, de Castro Suárez N, et al. [Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer](#). J Clin Pharmacol. 2015 Ago;55(8):888-98.

Sarduy MR, García I, Coca MA, Perera A, Torres LA, Valenzuela CM, et al. [Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer](#). Br J Cancer. 2015 May 12;112(10):1636-43.

Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, et al. [Safety and preliminary efficacy data of a novel casein kinase 2 \(CK2\) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies](#). BMC Cancer. 2009 May 13;9:146.

Solomon MT, Miranda N, Jorrín E, Chon I, Marinello JJ, Alert J, et al. [Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience](#). Cancer Biol Ther. 2014 May;15(5):504-9.

Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, et al. [Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial](#). BMC Cancer. 2013 Jun 19;13:299.

Sary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. [Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002](#). J Clin Oncol. 2014 Ene 20;32(3):174-84.

Vargas A, Mendoza I, Uranga R, González A, Martínez L, Caballero I, et al. [Efficacy and safety of iorEPOCIM for chemotherapy- or radiotherapy-induced anemia in pediatric cancer patients](#). MEDICC Rev. 2010 Jul;12(3):27-31.